PAL-222 transplant to treat stubborn skin ulcers.

Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer

This trial tests placing a PAL-222 transplant into adults' stubborn skin ulcers that have not healed with standard treatments to see if it is safe and helps healing.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 6 (estimated)
• Ages: 20 Years and up
• Sex: All
• Sponsor: PharmaBio Corporation (Industry-sponsored)
• Locations: 1 site (Kyoto, Shogoin-kawahara-cho, Sakyo-ku, Kyoto)
• Trial ID: NCT07016438 on ClinicalTrials.gov

What this trial studies

This is a single-arm interventional study in which each participant will receive one PAL-222 transplant placed directly into the target ulcer site. Safety endpoints include monitoring adverse events, changes in clinical laboratory data, and vital sign changes, with comparisons made to pre-transplant baseline. Eligible patients are adults with refractory skin ulcers that have not improved after at least four weeks of conservative care and with ulcer size of about 1–3 cm2 after debridement and no local infection. All procedures and follow-up visits take place at Kyoto University Hospital.

Who should consider this trial

Good fit: Ideal candidates are adults (20 years or older) with a single refractory skin ulcer that has decreased by less than 50% after ≥4 weeks of conservative treatment, measures about 1–3 cm2 after debridement, shows no local infection, and has adequate local perfusion.

Not a fit: Patients with active local infection, ulcers larger than the specified size range or with bone exposure exceeding 10% of the ulcer area, or with poor local perfusion below the required threshold are unlikely to benefit from this procedure.

Why it matters

Potential benefit: If successful, PAL-222 could help heal skin ulcers that have not responded to existing therapies and reduce ongoing wound care needs.

How similar studies have performed: Related cell- and tissue-transplant approaches for chronic ulcers have shown mixed but sometimes promising results in small studies, while PAL-222 itself appears to be a novel intervention with limited prior public data.

Eligibility criteria

Inclusion Criteria:

* (1) Patients aged 20 years or older at the time of obtaining consent (2) Patients with skin ulcers whose ulcer size has decreased by less than 50% compared to before the start of treatment even after 4 weeks or more of conservative standard treatment (3) Patients with an ulcer of 1 cm2 or more and 3 cm2 or less after debridement (4) Patients with ulcers within 5 cm from the ulcer to be treated (5) Patients with no signs of local infection in the ulcer to be treated (6) If the ulcer had the bone exposure, it needs to be within 10% of the ulcer area (7) Patients with skin reflux pressure of 30 mmHg or more at the treatment site (if the patient has an ulcer on the lower leg or foot) (8) Patients who have received a written explanation of this clinical trial from the principal investigator or clinical investigator, fully understood the information, and given their own written consent to participate in this clinical trial (9) Patients who are able to follow oral or written instructions from the principal investigator or clinical investigator

Exclusion Criteria:

* (1) Patients with any of the following systemic diseases

  1. Poorly controlled diabetes mellitus (HbA1c greater than 10% at the most recent examination within 28 days prior to enrollment)
  2. Hypoalbuminemia (serum albumin level less than 2 g/dL)
  3. Patients requiring continuous oral steroids (prednisolone equivalent greater than 10 mg per day) (2) Patients requiring general anesthesia or lumbar anesthesia during the study period for the following reasons

  <!-- -->

  1. When local anesthesia is not appropriate for debridement due to scarring or hardness of the wound
  2. Patients who are mentally disturbed, have involuntary movements, or are unable to keep the wound at rest during transplantation (3) Patients with a history of allergy to human serum albumin, trypsin, anesthetics used in this study, antiseptics, or covering materials (4) Patients with abnormal findings on hematology, hematochemistry, coagulation, or urinalysis at the time of screening that would be problematic for participation in the clinical trial (5) Patients with positive HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody, or syphilis serology at screening (6) Patients with severe blood disorders (if any of the following criteria are met)

  <!-- -->

  1. Hemoglobin less than 10.0 g/dL
  2. White blood cell count less than 3,000 /microliter
  3. Neutrophil count less than 1,500 / microliter
  4. Platelet count less than 75,000 / microliter (7) Patients with severe heart failure (NYHA cardiac function classification III-IV) (8) Patients with severe hepatic impairment (with a history of or complicated by fulminant hepatitis, cirrhosis, liver tumor, or any of the following criteria)

  <!-- -->

  1. Total bilirubin 1.5x (upper limit of reference value) or higher
  2. AST (GOP) 3.0x (upper limit of reference value) or more
  3. ALT (GPT) 3.0x (upper limit of reference value) or more
  4. ALP 2.5x (upper limit of reference value) or higher (9) Patients with severe renal impairment (creatinine greater than 2 mg/dL) (10) Patients diagnosed with or requiring treatment for malignancy within 5 years prior to obtaining consent (11) Pregnant or lactating women, or patients who wish to become pregnant during the study period (12) Patients whose anticoagulant or antiplatelet medication cannot be discontinued prior to the clinical trial, as determined by the attending physician of the relevant department (13) Patients with drug addiction or alcoholism (14) Patients who are currently participating in another clinical trial (15) Patients who have participated in this clinical trial once and had PAL-222 implanted (16) Patients who are judged to be inappropriate as subjects by the investigator or subinvestigator

Where this trial is running

Kyoto, Shogoin-kawahara-cho, Sakyo-ku, Kyoto

• Kyoto University Hospital — Kyoto, Shogoin-kawahara-cho, Sakyo-ku, Kyoto, Japan (Recruiting)

Study contacts

• Study coordinator: Hitoshi Kusano, M.D.

Conditions Refractory Skin Ulcer